Antibiotic Therapies for Urinary Tract Infections and Their Impact on the Gut Microbiota (ABIME)

February 20, 2026 updated by: University Hospital, Rouen
A urinary tract infection requires antibiotic treatment. While this treatment is intended to eliminate bacteria from the urine, it may also facilitate the development of resistant strains in the digestive tract. Patients are asked to provide stool samples on several occasions so that any potential side effects of this treatment on the digestive flora can be analysed.

Study Overview

Status

Completed

Conditions

Detailed Description

Each of us has billions of bacteria in our intestines that aid digestion (scientifically known as the gut microbiota), some of which can "mutate", i.e. adapt to resist antibiotics. Although this is usually harmless, these bacteria can sometimes cause infections.

Hence the importance of better understanding this phenomenon, known as the 'collateral effect on flora of otherwise beneficial antibiotic treatment'. The investigators already know that not all antibiotics are equivalent, with some having a stronger 'collateral effect'. However, the risk classification remains poorly understood.

Recent advances in laboratory stool analysis now make it possible to better analyse this phenomenon.

The ultimate goal is to identify treatment regimens that are both highly effective in treating urinary tract infections and have the least possible ecological impact.

Study Type

Observational

Enrollment (Actual)

61

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Rouen, France, 76031
        • CHU de ROUEN

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients will be recruited via the Emergency Department (ED).

Description

Inclusion Criteria:

  • Adult patient requiring hospitalisation
  • Diagnosis of urinary tract infection requiring systemic antibiotic therapy with ceftriaxone, piperacillin/tazobactam or temocillin
  • Collection of a stool sample possible before or within 24 hours of starting systemic antibiotic therapy
  • Patient who has read and understood the information letter and given their consent to participate in the research

Exclusion Criteria:

  • Minor patient
  • Patient hospitalised in an intensive care unit
  • Digestive stoma
  • Patient not affiliated with social security
  • Pregnant woman, woman in labour or breastfeeding woman
  • Person deprived of liberty by administrative or judicial decision
  • Person placed under judicial protection, guardianship or curatorship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessing the alteration of the gut microbiota induced by initial antibiotic therapy for urosepsis.
Time Frame: From enrollment to 30-35 days after the end of antibiotic treatment

Impact of initial antibiotic therapy on the increase in EC3GR enteric carriage defined as:

  • Positive EC3GR culture in stool sample 30-35 days after the end of antibiotic treatment (FT+30-35) in a patient with a negative (i.e. undetectable) EC3GR culture in stool sample on day 0 (D0)
  • Or a tenfold increase in the relative abundance of EC3GR between stool samples taken on D0 and FT-30-35 in patients with a positive EC3GR culture in stool samples taken on D0
From enrollment to 30-35 days after the end of antibiotic treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Rouen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 4, 2021

Primary Completion (Actual)

May 28, 2025

Study Completion (Actual)

May 28, 2025

Study Registration Dates

First Submitted

February 13, 2026

First Submitted That Met QC Criteria

February 13, 2026

First Posted (Actual)

February 20, 2026

Study Record Updates

Last Update Posted (Actual)

February 24, 2026

Last Update Submitted That Met QC Criteria

February 20, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019/329/OB

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urinary Tract Infection(UTI)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe